Table 3. Common and exclusive significant pathways for the case of breast cancer stages.
| Stage | Pathways | P-value | Genes |
|---|---|---|---|
| Stage I | cell communication | 6.42E-07 | LAMB3;KRT13;KRT8;LAMC2;KRT5;LMNB1;COL1A1;KRT18;COL5A1;KRT17;KRT15;COL5A2;SPP1 |
| cytokine receptor interaction | 0.000903 | CXCL11;CXCL9;IL6;CCL11;CCL7;IL20RA;LEPR;CXCL1;BMPR1B;CXCL13;CXCL3;CXCL2 | |
| metabolism of xenobiotics by cytochrome p450 | 0.001439 | ADH4;ADH1C;ADH1A;AKR1C1;AKR1C3;CYP3A5 | |
| 3 chloroacrylic acid degradation | 0.002961 | ADH4;ADH1C;ADH1A | |
| ecm receptor interaction | 0.00403 | COL1A1;COL5A1;LAMB3;COL5A2;SPP1;LAMC2 | |
| Stage II | cell communication | 1.48E-07 | COL17A1;LAMB3;COL11A1;LAMA3;KRT13;KRT8;LAMC2;KRT5;LMNB1;COL1A1;COMP;GJB2;KRT19;KRT18;IBSP;KRT17;KRT15;KRT37;COL5A2;KRT14;COL4A6;SPP1;DSG3;DSC1 |
| 3 chloroacrylic acid degradation | 0.000249 | ADH4;ALDH1A3;ADH1C;ALDH2;ADH1B;ADH1A | |
| cytokine receptor interaction | 0.001038 | CXCL9;CCL11;TNFRSF18;IL20RA;CXCL1;CXCL13;CXCL3;CXCL2;PRLR;CX3CL1;EGFR;GHR;BMP2;CXCL11;IL6;TPO;CCL7;LEP;TNFSF4;KIT;IL21R;LEPR;CCL28;IL17B | |
| ecm receptor interaction | 0.004466 | COL1A1;IBSP;LAMB3;SV2B;COL11A1;COL5A2;LAMA3;COL4A6;SPP1;SDC1;LAMC2 | |
| tyrosine metabolism | 0.005824 | ADH4;ALDH1A3;TPO;ADH1C;MAOB;ADH1B;MAOA;ADH1A | |
| fatty acid metabolism | 0.008441 | ADH4;ALDH1A3;ACADL;ADH1C;ALDH2;ADH1B;ADH1A | |
| bile acid biosynthesis | 0.0136 | ADH4;ALDH1A3;ADH1C;ALDH2;ADH1B;ADH1A | |
| glycerolipid metabolism | 0.021223 | ADH4;ALDH1A3;ADH1C;ALDH2;GPAM;ADH1B;ADH1A | |
| 1 and 2 methylnaphthalene degradation | 0.021512 | ADH4;ADH1C;ADH1B;ADH1A | |
| complement and coagulation cascades | 0.022486 | C6;C7;F12;CFI;PLAUR;C4BPA;F3;CFB | |
| *phenylalanine metabolism | 0.036024 | ALDH1A3;TPO;MAOB;MAOA | |
| Stage III | cell communication | 2.58E-09 | LAMB3;LAMA3;KRT13;KRT8;LAMC2;KRT5;LMNB1;COL1A1;COMP;KRT19;KRT18;IBSP;KRT17;KRT15;KRT37;COL5A2;KRT14;SPP1;DSG3 |
| 3 chloroacrylic acid degradation | 8.57E-05 | ADH4;ALDH1A3;ADH1C;ADH1B;ADH1A | |
| fatty acid metabolism | 0.001264 | ADH4;ALDH1A3;ACADL;ADH1C;ADH1B;ADH1A | |
| metabolism of xenobiotics by cytochrome p450 | 0.002315 | ADH4;ALDH1A3;ADH1C;ADH1B;ADH1A;AKR1C1;AKR1C3 | |
| 1 and 2 methylnaphthalene degradation | 0.002336 | ADH4;ADH1C;ADH1B;ADH1A | |
| tyrosine metabolism | 0.002709 | ADH4;ALDH1A3;ADH1C;MAOB;ADH1B;ADH1A | |
| glycerolipid metabolism | 0.003212 | ADH4;ALDH1A3;ADH1C;GPAM;ADH1B;ADH1A | |
| bile acid biosynthesis | 0.003433 | ADH4;ALDH1A3;ADH1C;ADH1B;ADH1A | |
| ecm receptor interaction | 0.007067 | COL1A1;IBSP;LAMB3;COL5A2;LAMA3;SPP1;LAMC2 | |
| cytokine cytokine receptor interaction | 0.008847 | CCL11;IL20RA;CXCL1;CXCL13;CXCL3;CXCL2;CXCL11;IL6;CCL7;LEP;IL21R;LEPR;CCL28 | |
| *glycolysis and gluconeogenesis | 0.023202 | ADH4;ALDH1A3;ADH1C;ADH1B;ADH1A | |
| *PPAR signaling pathway | 0.028896 | ACADL;MMP1;ADIPOQ;OLR1;ANGPTL4 | |
| complement and coagulation cascades | 0.032049 | C6;C7;PLAUR;C4BPA;CFB | |
| Stage IV | cytokine receptor interaction | 0.002012 | CXCL11;IL6;CCL11;CCL7;IL21R;LEPR;CXCL13;CXCL3;CXCL2 |
| cell communication | 0.005242 | COL1A1;KRT17;COL5A2;KRT14;SPP1;LMNB1 | |
| *toll like receptor signaling pathway | 0.029052 | CXCL11;IL6;SPP1;FOS | |
| ecm receptor interaction | 0.082661 | COL1A1;COL5A2;SPP1 | |
| complement and coagulation cascades | 0.048285 | PLAUR;C4BPA;F3 |
*Exclusive mechanisms for the specific Breast Cancer Stage.